1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow ReCode Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF RCT2100, Placebo, Ivacaftor - Cystic Fibrosis | Phase 2 | Active not recruiting | ReCode Therapeutics | 128 | 2024-02-01 | 2026-08-19 |
Cystic Fibrosis (1)
ivacaftor (1)
France (1) · Netherlands (1) · New Zealand (1) · United Kingdom (1) · United States (1)